Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
作者： Keith A. Hruska , Marc F. Charette , John Mccartney
DOI:
关键词:
摘要: The present invention provides reagents and methods for the treatment, pharmaceuticals use in prevention and/or of chronic renal failure other disorders subjects (particularly mammalian subjects) replacement therapy. involve conjoint administration ACE (Angiotensin-Converting Enzyme) inhibitors or Angiotensin II Receptor Antagonists (AIIRAs) with one more OP/BMP family proteins (morphogens, inducers morphogens, agonists corresponding morphogen receptors, etc.). also implantation cells induced AIIRAs those morphogens.
lens.org参考文章(14)
Barbara SmithKline Beecham Pharm. Olson, Nicholas SmithKline Beecham Pharm. Laping, Yuan SmithKline Beecham Pharm. Zhu, CRFG-1a, a target and marker for chronic renal failure ,(1998)
Randy Lee Webb, David Saul Cohen, Marc De Gasparo, Combination compositions containing benazepril or benazeprilat and valsartan ,(1996)
Howard R. Higley, Christopher A. Maack, Method of treating renal disease by administering igf-i and igfbp-3 ,(1994)
Slobodan Vukicevic, Kuber T. Sampath, Charles M. Cohen, Therapies for acute renal failure ,(1998)
Chi-Yin Ko, Hai Chih, Yu-Min Deng, Shing-Sheng Yang, Pre-wet system for a filter ,(1996)
Toshifumi Watanabe, Mami Ojima, Keiji Kusumoto, Preventives/remedies for portal hypertension ,(2001)
Anne-Lise Kamper, Discussion: Effect of enalapril on the progression of chronic renal failure Journal of Diabetes and Its Complications. ,vol. 6, pp. 272- ,(1992) , 10.1016/1056-8727(92)90078-Y
Colin C. Barnes, DIABETIC NEPHROPATHY : ARE WE MAKING PROGRESS IN DELAYING RENAL FAILURE ? Clinical Biochemistry. ,vol. 26, pp. 318- 319 ,(1993) , 10.1016/0009-9120(93)90136-T
Thangavel Kuberasampath, David C. Rueger, Osteogenic proteins and polypeptides ,(1988)
Charles M. Cohen, Kuber T. Sampath, Morphogen treatment for chronic renal failure ,(1997)